1-3 of 3
Lisa M. Butler
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer

Linh N.K. Tran, Ganessan Kichenadasse, Lisa M. Butler, Margaret M. Centenera, Katherine L. Morel, Rebecca J. Ormsby, Michael Z. Michael, Karen M. Lower, Pamela J. Sykes
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (12): 2689–2700.
https://doi.org/10.1158/1535-7163.MCT-17-0074
Published: 03 December 2017
View article titled, The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer
Open the PDF for The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract CN08-05: A combinatorial approach to targeting androgen receptor signaling in prostate cancer.

Wayne D. Tilley, Margaret M. Centenera, Sarah L. Carter, Luke A. Selth, Lisa M. Butler
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): CN08-05.
https://doi.org/10.1158/1535-7163.TARG-11-CN08-05
Published: 12 November 2011
View article titled, Abstract CN08-05: A combinatorial approach to targeting androgen receptor signaling in prostate cancer.
Journal Articles

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation

Deborah L. Marrocco, Wayne D. Tilley, Tina Bianco-Miotto, Andreas Evdokiou, Howard I. Scher, Richard A. Rifkind, Paul A. Marks, Victoria M. Richon, Lisa M. Butler
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (1): 51–60.
https://doi.org/10.1158/1535-7163.MCT-06-0144
Published: 19 January 2007
View article titled, Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
Open the PDF for Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation in another window